



Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA), Scientific Committee members and experts

Public declaration of interests

I, **Christiane De Boeck**

Organisation/Company: University of Leuven

Country: Belgium

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment with a Company

No Interest Declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
07/2011-(current)	Galapagos	preclinical programs / cystic fibrosis	
05/2010-(current)	Ablynx	preclinical programs / respiratory syncytial virus	
01/2005-12/2005	Janssens pharma	preclinical program / respiratory syncytial virus	

2.3 Strategic Advisory Role

Period	Company	Products	Therapeutic Indication
01/2009-(current)	Vertex	CFTR correctors, potentiators / cystic fibrosis	
01/2009-(current)	Gilead	inhaled antibiotics / cystic fibrosis, non CF bronchiectasis	
01/2009-12/2011	Pharmaxis	mannitol	cystic fibrosis, non CF bronchiectasis
01/2009-12/2010	Boehringer Ingelheim	tiotropium	cystic fibrosis
01/2005-12/2009	Baxter	Immunoglobulins / immunodeficiency	
01/2009-12/2010	Bayer	inhaled antibiotics / cystic fibrosis	
01/2007-12/2010	Biovitrum	Pancreatic enzymes / cystic fibrosis	
01/2008-12/2010	Inspire	denufisol	cystic fibrosis
01/2008-12/2011	PTC	ataluren	cystic fibrosis
06/2010-(current)	Aptalis	Pancreatic enzymes	cystic fibrosis

2.4 Current Financial Interests

No Interest Declared

2.5 Patent

No Interest Declared

2.6 Principal Investigator

Period	Company	Products	Therapeutic Indication
06/2012-(current)	Vertex	Ivacaftor	cystic fibrosis
07/2012-(current)	Gilead Sciences	Aztreonam	Cystic fibrosis
09/2010-05/2012	Boehringer Ingelheim	tiotropium	cystic fibrosis
01/2009-(current)	Vertex	Vx-809	cystic fibrosis
12/2008-12/2010	Pharmaxis Ltd	mannitol	cystic fibrosis
11/2008-05/2012	PTC therapeutics	PTC124	Cystic Fibrosis

2.7 Investigator

Period	Company	Products	Therapeutic Indication
01/2010-(current)	Vertex	VX-809	cystic fibrosis
01/2009-12/2011	Boehringer Ingelheim	tiotropium bromide	cystic fibrosis

2.8 Grant / Funding to Institution

No Interest Declared

2.9 Family Member Interest

No Interest Declared

SECTION 3: CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document

other than for the purposes of my work in connection with EMA activities.

- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the EMA website.

Full Name:	Christiane De Boeck
Date:	2012-05-22

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template